TAKEDA PHARMACEUTICAL COMPANY LIMITED Takeda Pharmaceutical Company Limited Share Price London S.E.
Equities
0A87
US8740602052
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.07 USD | +0.12% |
|
-0.83% | -8.12% |
| Sales 2024 | 4,264B 27.31B 2,268B | Sales 2025 * | 4,230B 27.09B 2,251B | Capitalization | 6,593B 42.22B 3,507B |
|---|---|---|---|---|---|
| Net income 2024 | 144B 923M 76.64B | Net income 2025 * | 114B 731M 60.72B | EV / Sales 2024 | 1.54 x |
| Net Debt 2024 * | 3,771B 24.15B 2,006B | Net Debt 2025 * | 3,993B 25.57B 2,124B | EV / Sales 2025 * | 2.5 x |
| P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
61
x | Employees | 49,095 |
| Yield 2024 |
4.49% | Yield 2025 * |
4.6% | Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Takeda Pharmaceutical Company Limited
More recommendations
More press releases
More news
| 1 day | +0.12% | ||
| 1 week | -0.83% | ||
| Current month | -1.69% | ||
| 1 month | -1.66% | ||
| 3 months | -10.30% | ||
| 6 months | -7.70% | ||
| Current year | -8.12% |
1 week
12.97
13.47
1 month
12.8013.47
Current year
12.8015.07
1 year
12.8016.81
3 years
12.3017.40
5 years
12.3019.92
10 years
12.3019.92
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 01/14/01 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 01/22/01 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 01/12/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 01/16/01 | |
Ian Clark
BRD | Director/Board Member | 62 | 01/19/01 |
Steven Gillis
BRD | Director/Board Member | 71 | 01/19/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 13.46 | +1.23% | 394 |
| 31/24/31 | 13.3 | +1.84% | 1,654 |
| 30/24/30 | 13.06 | +0.50% | 634 |
| 29/24/29 | 12.99 | -0.91% | 1,729 |
| 28/24/28 | 13.11 | -0.54% | 1,627 |
Delayed Quote London S.E., May 23, 2024 at 07:58 pm IST
More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
04/06/2024
- Sleep Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,202
JPY
Average target price
4,801
JPY
Spread / Average Target
+14.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +42.60% | 739B | |
| +32.34% | 598B | |
| -5.74% | 353B | |
| +17.79% | 318B | |
| +3.37% | 285B | |
| +16.47% | 240B | |
| +9.26% | 210B | |
| -5.07% | 206B | |
| +6.74% | 164B |
- Stock Market
- Equities
- 4502 Stock
- 0A87 Stock
